Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CB2 cannabinoid receptor-mediated peripheral antinociception.

Philip T Malan1, Mohab M Ibrahim, Hongfeng Deng

  • 1Department of Anesthesiology and Pharmacology, University of Arizona, Tucson, AZ 85724, USA Departments of Medicinal Chemistry and Molecular and Cell Biology, The University of Connecticut, Storrs, CT 06269, USA.

Pain
|August 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception.

Drug and alcohol dependence·2026
Same author

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026
Same author

Library docking for Cannabinoid-2 Receptor ligands.

bioRxiv : the preprint server for biology·2026
Same author

Dopamine, γ-aminobutyric acid, and glutamate balance in the nucleus accumbens shell: Differential effects of cannabinoid 1 receptor agonists Δ<sup>9</sup>-Tetrahydrocannabinol, AM11101, and AM8936.

Neuropharmacology·2026
Same author

Effects of the neutral CB1 receptor antagonist AM6527 on spontaneous, consummatory, and motivated behavior in mice.

Psychopharmacology·2025
Same author

Exceptionally Potent Chiral Anandamide Analogs.

Journal of medicinal chemistry·2025

CB(2) receptors, primarily outside the central nervous system, can produce pain relief. Selective CB(2) receptor activation in the paw reduces pain without causing central nervous system side effects.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pain Research

Background:

  • Cannabinoid receptor agonists are known pain relievers.
  • CB(1) receptors are heavily implicated in antinociception.
  • The role of peripheral CB(2) receptors in pain relief remains largely unknown.

Purpose of the Study:

  • To investigate the antinociceptive capacity of CB(2) receptors.
  • To determine if CB(2) receptor activation can produce pain relief without central nervous system (CNS) effects.

Main Methods:

  • Utilized AM1241, a selective CB(2) receptor agonist, in rodent models.
  • Administered AM1241 locally to the hindpaw and systemically.
  • Used selective CB(1) and CB(2) receptor antagonists (AM251 and AM630) to confirm receptor involvement.

Related Experiment Videos

  • Assessed for CNS-related cannabinoid side effects (hypothermia, catalepsy, activity, ambulation).

    • Main Results:

    • Local injection of AM1241 into the hindpaw produced antinociception to thermal stimuli.
    • Antinociceptive effects were blocked by a CB(2) antagonist (AM630) but not a CB(1) antagonist (AM251).
    • Systemic AM1241 also produced antinociception, dependent on local paw administration of the antagonist.
    • AM1241 did not induce CNS side effects, unlike a mixed CB(1)/CB(2) agonist.

    Conclusions:

    • CB(2) receptors mediate peripheral antinociception.
    • Activation of peripheral CB(2) receptors provides pain relief without CNS side effects.
    • CB(2) receptor agonists show potential for clinical pain management with an improved side effect profile.